Magnetic Resonance Fingerprinting of Patients with Gliomas at 3T

Magnetic Resonance Fingerprinting of Patients with Gliomas at 3T - MRF_Gliomas

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00013761

Enrollment

Registered

2018-02-01

Start date

2018-02-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GLIOMAS D33 C71

Interventions

Group 1: Application of the MRF protocol and conventional, advanced MR brain tumor protocol in patients with gliomas at 3T

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Written, informed consent to participate in the present study - Age 18 years or older - ECOG performance status 0-2 - Strong radiological suspicion of supratentorial glioma (low- or high-grade) - Patient scheduled for neurosurgical biopsy/resection of the brain lesion

Exclusion criteria

Exclusion criteria: - MR contraindications: metallic implants (pacemaker, surgical clips, prosthetic heart valves, cochlear implants, etc.), claustrophobia, pregnancy - Uncontrolled epileptic seizures - Prior diagnosis of invasive cancer or glioma - Prior chemo- or radiotherapy

Design outcomes

Primary

Measure	Time frame
Our hypothesis is that Magnetic Resonance Fingeprinting (MRF) will offer a fast, single sequence for the evaluation of brain tumors, which may replace several conventional MR sequences, currently used in advanced brain tumor protocols. The performace of MRF will be tested at conventional 3T MR scanner on 20 patients with low-grade gliomas and 30 patients with high-grade gliomas within 36 month of study duration.	—

Measure

Time frame

Our hypothesis is that Magnetic Resonance Fingeprinting (MRF) will offer a fast, single sequence for the evaluation of brain tumors, which may replace several conventional MR sequences, currently used in advanced brain tumor protocols. The performace of MRF will be tested at conventional 3T MR scanner on 20 patients with low-grade gliomas and 30 patients with high-grade gliomas within 36 month of study duration.

—

Countries

Austria

Contacts

Public ContactSiegfried Trattnig

Medical University of Vienna

siegfried.trattnig@meduniwien.ac.at+431404006460

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026